Table 1.
Demographic and clinical data in EOPD/LOPD patients and normal controls.
| Group N | EOPD | Young NC | EOPD vs. controls P-value | LOPD | Old NC | LOPD vs. controls P-value | EOPD vs. LOPD P-value |
|---|---|---|---|---|---|---|---|
| N (female) | 18 (8) | 19 (10) | 0.62♦ | 21 (9) | 18 (10) | 0.50♦ | 0.92♦ |
| Age (Y) | 45.4 ± 6.07 | 45.8 ± 3.55 | 0.39▲ | 63.6 ± 4.84 | 61.7 ± 9.73 | 0.21▲ | <0.001⋆ |
| Disease duration (Y) | 3.04 ± 1.99 | NA | 3.1 ± 1.78 | NA | 0.43▲ | ||
| Disease stage(H&Y) | 2.03 ± 0.78 | NA | 2.0 ± 0.62 | NA | 0.49▲ | ||
| UPDRS | 37.8 ± 9.86 | NA | 39.3 ± 10.62 | NA | 0.3▲ | ||
| UPDRS III | 16.94 ± 5.07 | NA | 18.61 ± 4.51 | NA | 0.29▲ | ||
| MMSE | 27.8 ± 1.56 | 29.2 ± 0.91 | 0.003▲ | 26.5 ± 2.16 | 27.2 ± 2.74 | 0.21▲ | 0.065⋆ |
| HAMD | 6.38 ± 2.06 | 5.47 ± 1.87 | 0.089▲ | 6.52 ± 2.81 | 5.72 ± 2.10 | 0.17▲ | <0.001⋆ |
| Side initially affected, R/L | 11/7 | NA | 10/11 | NA | 0.40● | ||
| L-Dopa dose (mg/d) | 395.8 ± 278.7 | NA | 440.5 ± 187.9 | NA | 0.28▲ | ||
| No. (%) of patients treated with pramipexole | 14 (78) | NA | 16 (76) | NA | 0.91● | ||
| No. (%) of patients treated with piribedil | 9 (50) | NA | 14 (67) | NA | 0.29● |
NC, Normal control; EOPD, Early-onset Parkinson's disease patients; LOPD, Late-onset Parkinson's disease patients.
▲: Two sample t-test.
●: Pearson χ2-test.
⋆: ANOVA analysis with two factors.
♦: Chi-square test.